News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Are SGLT2 inhibitors cardioprotective in wild-type ATTR-CM patients?
05 Nov 2024
byAudrey Abella
The use of sodium glucose cotransporter-2 (SGLT2) inhibitors nearly halves the risk of all-cause mortality at 3 years in patients with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) and type 2 diabetes (T2D), findings from an observational study suggest.
05 Nov 2024

Data support abrocitinib use beyond 2 years in adolescents with AD
05 Nov 2024
byMike Ng
Treating adolescents with moderate-to-severe AD with the JAK1-selective inhibitor abrocitinib has demonstrated an acceptable long-term safety profile and maintained efficacy for up to 112 weeks, as shown in an adolescent-focused post hoc analysis of 5 phase III trials
05 Nov 2024







